Sumitomo Mitsui Trust Group
ARCT icon

Sumitomo Mitsui Trust Group’s Arcturus Therapeutics ARCT Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Sell
1,963,123
-325,812
-14% -$2.57M 0.01% 650
2026
Q1 		$17.7M Buy
2,288,935
+262,347
+13% +$1.91M 0.01% 630
2025
Q4 		$12.4M Buy
2,026,588
+78,753
+4% +$851K 0.01% 664
2025
Q3 		$35.9M Buy
1,947,835
+115,368
+6% +$1.85M 0.02% 559
2025
Q2 		$23.8M Sell
1,832,467
-93,617
-5% -$1.11M 0.01% 617
2025
Q1 		$20.4M Sell
1,926,084
-138,966
-7% -$2.21M 0.01% 637
2024
Q4 		$35M Sell
2,065,050
-210,665
-9% -$3.97M 0.02% 541
2024
Q3 		$52.8M Buy
2,275,715
+712,650
+46% +$15.2M 0.04% 436
2024
Q2 		$38.1M Buy
1,563,065
+286,546
+22% +$8.69M 0.03% 498
2024
Q1 		$43.1M Sell
1,276,519
-44,133
-3% -$1.56M 0.03% 534
2023
Q4 		$41.6M Sell
1,320,652
-67,922
-5% -$1.61M 0.03% 528
2023
Q3 		$35.5M Sell
1,388,574
-16,358
-1% -$504K 0.03% 551
2023
Q2 		$40.3M Sell
1,404,932
-16,393
-1% -$446K 0.03% 533
2023
Q1 		$34.1M Sell
1,421,325
-27,735
-2% -$498K 0.03% 597
2022
Q4 		$24.6M Sell
1,449,060
-10,355
-0.7% -$181K 0.02% 667
2022
Q3 		$21.6M Buy
1,459,415
+23,221
+2% +$390K 0.02% 688
2022
Q2 		$22.6M Buy
1,436,194
+34,116
+2% +$669K 0.02% 696
2022
Q1 		$37.8M Buy
1,402,078
+44,606
+3% +$1.14M 0.03% 612
2021
Q4 		$50.2M Sell
1,357,472
-1,060
-0.1% -$43.2K 0.03% 534
2021
Q3 		$64.9M Buy
1,358,532
+143,631
+12% +$6.44M 0.04% 465
2021
Q2 		$41.1M Buy
1,214,901
+899,089
+285% +$30.4M 0.02% 598
2021
Q1 		$13M Buy
315,812
+181,208
+135% +$10.8M 0.01% 756
2020
Q4 		$5.84M Buy
134,604
+3,434
+3% +$233K ﹤0.01% 826
2020
Q3 		$5.63M Sell
131,170
-15,182
-10% -$754K ﹤0.01% 812
2020
Q2 		$6.84M Sell
146,352
-108,714
-43% -$3.75M ﹤0.01% 779
2020
Q1 		$3.47M Sell
255,066
-25,482
-9% -$326K ﹤0.01% 816
2019
Q4 		$3.05M Sell
280,548
-17,982
-6% -$188K ﹤0.01% 857
2019
Q3 		$3.07M Buy
298,530
+168,556
+130% +$1.82M ﹤0.01% 833
2019
Q2 		$1.23M Buy
+129,974
New +$954K ﹤0.01% 880

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ARCT Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Arcturus Therapeutics (ARCT) stake by 14% in Q2 2026, selling an estimated $2.57M and leaving 1,963,123 shares worth $13.2M. The position accounts for 0.01% of the portfolio, ranked #650.

Sumitomo Mitsui Trust Group first reported a position in ARCT in Q2 2019 and has held it in 29 quarters since. The position peaked at $64.9M in Q3 2021. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 1,963,123 shares of Arcturus Therapeutics worth $13.2M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 325,812 Arcturus Therapeutics shares in Q2 2026, an estimated $2.57M.
  • Arcturus Therapeutics made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #650 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Arcturus Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Sumitomo Mitsui Trust Group's Arcturus Therapeutics position peaked at $64.9M in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.